Refractory cutaneous necrotizing vasculitis. Successful sulfone therapy;Therapierefraktäre kutane nekrotisierende vaskulitis: Erfolgreiche sulfontherapie

Hautarzt

Volumn 57, Issue 1, 2006, Pages 47-50

  Seybold, H ^a   Simon, M ^a   Schuler, G ^a   Luftl M ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

DADPS; Immunomodulators; Necrotizing vasculitis; Sulfones

Indexed keywords

CYCLOPHOSPHAMIDE; DAPSONE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CASE REPORT; DISEASE COURSE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE ORGAN FAILURE; NECROTIZING ARTERITIS; REMISSION; SKIN INFLAMMATION; SKIN NECROSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VASCULITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DAPSONE; DRUG RESISTANCE; FEMALE; HUMANS; NECROSIS; SKIN DISEASES, VASCULAR; TREATMENT FAILURE; TREATMENT OUTCOME; VASCULITIS;

EID: 31744440033     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-004-0889-y     Document Type: Article

References (14)

1. Fauci AS, Haynes BF, Katz P, Wolff SM (1983) Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98: 76-85
2. Fiorentino DF (2003) Cutaneous vasculitis. J Am Acad Dermatol 48: 311-340
3. Fredenberg MF, Malkinson FD (1987) Sulfone therapy in the treatment of leukocytoclastic vasculitis. J Am Acad Dermatol 16: 772-778
4. Fukuhara K, Urano Y, Kimura S, Hori K, Arase S (2000) Pyoderma gangrenosum with rheumatoid arthritis and pulmonary aseptic abscess responding to treatment with dapsone. Br J Dermatol 139: 556-558
5. Grabbe J, Haas N, Moller A, Henz BM (2000) Erythema elevatum et diutinum - evidence for disease-dependent leucocyte alterations and response to dapsone. Br J Dermatol 143: 415-420
6. Hunder GG, Arend WP, Bloch DA et al. (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 33: 1065-1067
7. Jennette JC, Falk RJ, Andrassy K et al. (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187-192
8. Nürnberg W, Grabbe J, Czarnetzki BM (1995) Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline. Acta Derm Venereol 75: 54-56
9. Sharquie KE, Najim RA, Abu-Raghif AR (2002) Dapsone in Behcet's disease: a double-blind, placebo-controlled, cross-over study. J Dermatol 29: 267-279
10. Thomas-Golbanov C, Sridharan S (2001) Novel therapies in vasculitis. Expert Opin Invest Drugs 10: 1279-1289
11. Thuong-Nguyen V, Kadunce DP, Hendrix JD, Gammon WR, Zone JJ (1993) Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Invest Dermatol 100: 349-355
12. Van de Kerkhof PC (1994) On the efficacy of dapsone in granuloma faciale. Acta Derm Venereol 74: 61-62
13. Wozel G (1996) Dapson - Pharmakologie, Wirkmechanismus und klinischer Einsatz. Thieme, Stuttgart New York, S 24-48
14. Wozel G, Blasum C, Winter C, Gerlach B (1997) Dapsone hydroxylamine inhibits the LTB-4-induced chemotaxis of polymorphonuclear leukocytes into human skin: results of a pilot study. Inflamm Res. 46: 420-422